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Abstract
We consider designs for cancer trials which allow each medical cen-
tre to treat only a limited number of cancer types with only a limited
number of drugs. We specify desirable properties of these designs, and
prove some consequences. Then we give several different constructions.
Finally we generalize this to three or more factors, such as biomarkers.
1 First design problem
1.1 The problem
This problem was posed by Valerii Fedorov at the workshop on Design and
Analysis of Experiments in Healthcare held at the Isaac Newton Institute
for Mathematical Sciences at Cambridge, U.K. in July 2015. The context
is basket trials, where several different drugs are treated on several different
diseases in a single protocol which involves many medical centres: see Der-
haschung et al. (2016) and Woodcock & LaVange (2017). The combinatorial
properties listed below have been proposed by Fedorov & Leonov (2018) as
potentially giving optimal designs, which may give a benchmark for designs
which are achievable in practice.
A trial is being designed to compare several drugs for their effects on
several different types of cancer. In order to keep the protocol simple for
each medical centre involved, it is proposed to limit each medical centre
to only a few of the cancer types and only a few of the drugs. Let v1 be
the number of cancer types, v2 the number of drugs, and b the number of
medical centres. The following properties are desirable:
(a) all medical centres involve the same number, say k1, of cancer types,
where k1 < v1;
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(b) all medical centres use the same number, say k2, of drugs, where k2 <
v2;
(c) each pair of distinct cancer types are involved together at the same
non-zero number, say λ11, of medical centres;
(d) each pair of distinct drugs are used together at the same non-zero
number, say λ22, of medical centres;
(e) each drug is used on each type of cancer at the same number, say λ12,
of medical centres.
The inequalities in conditions (a) and (b) force the medical centres to
be incomplete both for cancer types and for drugs. Insisting that the pa-
rameters in conditions (c) and (d) are non-zero is necessary to prevent the
confounding of either cancer types or drugs with medical centres.
For brevity, from now on the medical centres will be referred to as blocks.
Figure 1 shows such a design for six cancer types and five drugs using 10
blocks; it has k1 = 3 and k2 = 2.
Conditions (a) and (c) specify that the design for cancer types is a bal-
anced incomplete-block design, also known as a 2-design, or, more specifi-
cally, a 2-(v1, k1, λ11) design. Likewise, conditions (b) and (d) specify that
the design for drugs is a 2-design. We call these the C-design and the D-
design respectively.
We shall call a design satisfying conditions (a)–(e) a 2-part 2-design or
2-part balanced incomplete block design. These are not the same as the
bipartite designs defined by Hoffman & Liatti (1995).
1.2 Previous work
In Section 2 we concentrate on designs with only two different factors (cancer
types and drugs), before generalizing to three or more factors in Section 3.
This is partly to help the reader to become familiar with the ideas, and
partly because this case seems likely to be of practical importance in the
clinical context described.
The more general case has already been considered by Sitter (1993),
Mukerjee (1998) and Hedayat et al. (1999, Section 10.8). Because condi-
tions (a)–(d) specify balanced incomplete-block designs and condition (e)
is reminiscent of the definition of orthogonal multi-array given by Brickell
(1984), Sitter (1993) called these designs balanced orthogonal multi-arrays.
Brickell’s original definition was essentially a generalization of orthogonal
arrays of strength two and minimal size, so it included the conditions that b
2
Figure 1: Design for 6 cancer types and 5 drugs, using 10 blocks; each block
has 3 cancer types and 2 drugs.
3
is a square and λ12 = 1. Sitter (1993) acknowledged that he was removing
those conditions.
However, the original definition of orthogonal multi-array continues to
be in use in many areas. They give an alternative definition of semi-Latin
squares: see Bailey (1992) and Soicher (1999, 2013). Dually, they are used
in factorial designs: see Bailey (2011). Phillips & Wallis (1996) used them in
the study of tournaments. They are used in cryptography: see, for example,
Anthony et al. (1990) and Martin et al. (1992). Recently, Li et al. (2015)
have generalized them to strength t, so that b is a t-th power of an integer.
This generalization seems to be within the spirit of the original definition,
whereas Sitter’s does not.
Thus we think that “2-part 2-design” (or, more generally, a multi-part
2-design) is a more suitable name.
Sitter (1993) also allowed the block size within each type to vary. Muk-
erjee (1998) called the balanced orthogonal multi-arrays proper when this is
not allowed. He also restricted attention to the case where ki < vi, unlike
Sitter (1993). Both allowed λii to be zero, which permits confounding: in
Table 1 of Mukerjee (1998) one type has its levels confounded with blocks.
Mukerjee (1998) gave two general constructions for designs of this type.
We shall comment on the relationship of these to our constructions at the
relevant places.
1.3 Representing the designs
How should we represent a design of this type? Each block has all combi-
nations of k1 cancer types with k2 drugs, so a full display would show bk1k2
items. For example, in the design in Fig. 1, Block 1 contains the ordered
pairs
(C1,D1), (C1,D5), (C2,D1), (C2,D5), (C3,D1), (C3,D5).
It might be clearer to show these in rectangular form:
(C1,D1) (C1,D5)
(C2,D1) (C2,D5)
(C3,D1) (C3,D5)
The people running the clinical trial need this full representation.
A dual way to represent the design is to use a v1 × v2 rectangle with
λ12 entries per cell. Equation (3) below shows that this contains the same
number of items as the full representation. The rows are labelled by the
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D1 D2 D3 D4 D5
C1 1, 2 2, 3 3, 4 4, 5 1, 5
C2 1, 6 7, 10 4, 6 4, 7 1, 10
C3 1, 9 3, 7 3, 8 7, 9 1, 8
C4 6, 9 3, 10 3, 6 5, 9 5, 10
C5 2, 6 2, 7 6, 8 5, 7 5, 8
C6 2, 9 2, 10 4, 8 4, 9 8, 10
Block Cancer types Drugs
1 C1, C2, C3 D1, D5
2 C1, C5, C6 D1, D2
3 C1, C3, C4 D2, D3
4 C1, C2, C6 D3, D4
5 C1, C4, C5 D4, D5
6 C2, C4, C5 D1, D3
7 C2, C3, C5 D2, D4
8 C3, C5, C6 D3, D5
9 C3, C4, C6 D1, D4
10 C2, C4, C6 D2, D5
(a) Dual representation (b) Concise representation
Figure 2: Alternative representations of the design in Fig. 1. In the dual
representation, the rows and columns of the rectangle are labelled by cancer
types and drugs respectively, and each entry in each cell is the name of a
block.
cancer types, and the columns by the drugs. The name of each block is
shown in each cell (i, j) for which the combination of cancer type i and drug j
occurs in that block. Figure 2(a) shows the design in Fig. 1 in this format.
This dual representation does not extend easily to the generalizations of the
problem in Sections 3–4.
The most concise way to represent the design is simply to list, for each
block, the cancer types and drugs allocated to it. This list has b(k1 + k2)
items. This representation was used by Sitter (1993) and Mukerjee (1998).
Figure 2(b) gives the concise representation of the design in Fig. 1.
We shall use the concise representation for the remainder of this paper.
However, it can be misinterpreted when removed from the practical context.
For example, the reader might think that Block 1 in Fig. 2(b) contains five
treatments, those in the union of the sets {C1,C2,C3} and {D1,D5}, rather
than the six treatment combinations in the cartesian product of these sets.
This misinterpretation gives a block design for v1+v2 treatments in b blocks
of size k1 + k2, which we call the zipped form of the original design.
Figure 1 avoids this problem, but at the cost of repeating the information
about the drugs in each block. This format contains bk1k2 items, as many
as the full representation, but it seems easier to read.
Let N1 be the v1 × b incidence matrix of cancer types in blocks in the
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zipped version of the design. The (i, j)-entry is 1 if cancer type i occurs in
block j; otherwise, it is 0. Let N2 be the analogous v2 × b incidence matrix
for drugs in blocks. Then the incidence matrices for the full design are k2N1
and k1N2 respectively, not allowing for the unknown number of times that
each combination will eventually be used in any block.
1.4 Comparison with other designs
At first sight, the design in Fig. 1 appears to be a block design for two treat-
ment factors C and D. However, there are important differences between
this and previous designs. In our application, the medical centre represented
by Block 1 will accept into the trial only patients with cancer types 1, 2 or 3.
It has no control in advance over how many such patients will present them-
selves. For each of these three cancer types, it will randomize approximately
equal numbers of patients to drugs 1 and 5 and placebo, or, in a variant of
the original proposal, approximately one quarter each to placebo, drug 1,
drug 5 and their combination.
Sitter (1993) introduced his designs for use in sampling. In designed
experiments, Mukerjee (1998) envisaged a completely different sort of appli-
cation from the one we describe here. In that, each block represents a single
observational unit. For each factor, subsets of the levels are applied, rather
than single levels. For example, a group of k1 people might be needed, all
playing similar roles, or a hybrid variety of wheat might be bred from k2
pure lines. See also Bailey (1992). In this context, it is not problematic to
have λii = 0 (so that ki = 1) for either i = 1 or i = 2.
In classical factorial designs with blocks of size k, from Yates (1933),
Fisher (1935, 1942) and Bose (1947) onwards, combinations of factor levels
do not occur more than once in any block: thus k1 = k2 = k. Moreover,
the subsets of combinations allocated to blocks are chosen depending on
various assumptions about main effects and interactions. For example, if
v1 = v2 = 3 and there are six blocks of three plots each then the design in
Fig. 3(a) permits estimation of both main effects with full efficiency and all
interaction contrasts with efficiency factor 1/2.
The dual form of this design is shown in Fig. 3(b). The positions of
the block names show clearly how the block design was constructed from
a pair of mutually orthogonal Latin squares. However, unlike in Fig. 2(a),
no block name occurs more than once in any row or column. Consequently,
the occurrences of each block name do not have the rectangular layout that
they do in Fig. 2(a).
Later in the twentieth century there was much literature on incomplete-
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Block 1 (C1, D1) (C2, D2) (C3, D3)
Block 2 (C1, D2) (C2, D3) (C3, D1)
Block 3 (C1, D3) (C2, D1) (C3, D2)
Block 4 (C1, D1) (C2, D3) (C3, D2)
Block 5 (C1, D2) (C2, D1) (C3, D3)
Block 6 (C1, D3) (C2, D2) (C3, D1)
D1 D2 D3
C1 1, 4 2, 5 3, 6
C2 3, 5 1, 6 2, 4
C3 2, 6 3, 4 1, 5
(a) Usual representation (b) Dual representation
Figure 3: Classical factorial design for two 3-level treatment factors in
6 blocks of size 3.
Block 1 (C3, D4) (C4, D3) (C6, D1)
Block 2 (C4, D5) (C5, D4) (C6, D2)
Block 3 (C5, D1) (C1, D5) (C6, D3)
Block 4 (C1, D2) (C2, D1) (C6, D4)
Block 5 (C2, D3) (C3, D2) (C6, D5)
Block 6 (C1, D1) (C4, D2) (C3, D5)
Block 7 (C2, D2) (C5, D3) (C4, D1)
Block 8 (C3, D3) (C1, D4) (C5, D2)
Block 9 (C4, D4) (C2, D5) (C1, D3)
Block 10 (C5, D5) (C3, D1) (C2, D4)
D1 D2 D3 D4 D5
C1 6 4 9 8 3
C2 4 7 5 10 9
C3 10 5 8 1 6
C4 7 6 1 9 2
C5 3 8 7 2 10
C6 1 2 3 4 5
(a) Usual representation (b) Dual representation
Figure 4: Block design for two non-interacting sets of treatments, with v1 =
6, v2 = 5, b = 10 and k = 3.
block designs for two non-interacting treatment factors with each treatment
combination occurring once, so that v1v2 = bk and k1 = k2 = k, where k is
the block size. For example, Preece (1966b) gave the design in Fig. 4(a).
The dual form is in Fig. 4(b).
Many authors required the block design for each treatment factor sep-
arately to be balanced. This is the analogue of conditions (a)–(d) when
k1 = k2. From Agrawal (1966) and Preece (1966a) onwards, another condi-
tion was often imposed, eventually called adjusted orthogonality by Eccleston
& Russell (1977): the product N˜1N˜
>
2 should have all its entries equal, where
N˜1 and N˜2 are the v1×b and v2×b incidence matrices for the first and second
treatment factors, respectively, in blocks. Although this is a consequence of
condition (e), it is not equivalent to it. The duals of designs satisfying these
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conditions were called triple arrays by McSorley et al. (2005). The design
in Fig. 4(b) is a triple array.
In spite of the similar conditions that they satisfy, triple arrays are not
special cases of 2-part 2-designs, nor vice versa. In a triple array, no block
name occurs more than once in any row or column. In the dual form of a
2-part 2-design, any block name that occurs in a given row must occur k2
times in that row. A consequence of the “non-zero part” of condition (d) is
that k2 > 1.
Apart from the designs given by Preece et al. (2005), infinite families
of triple arrays have proved frustratingly hard to find: see Bailey (2017,
Section 13). By contrast, in Sections 2 and 4 of this paper we give many
simple constructions of 2-part 2-designs and their generalizations.
1.5 Conditions on parameters
An ordinary block design is said to be α-resolved if its set of blocks can be
partitioned into classes in such a way that each treatment occurs α times
in each class. This terminology does not extend easily to 2-part 2-designs,
because cancer types may occur in different numbers of blocks from drugs.
We propose calling a 2-part block design c-partitionable if the set of blocks
can be grouped into c classes of b/c blocks each, in such a way that every
cancer type occurs the same number of times in each class and every drug
occurs the same number of times in each class.
Theorem 1 If there is a 2-part 2-design with the parameters given in condi-
tions (a)–(e), then each cancer type occurs in r1 blocks and each drug occurs
in r2 blocks, where
r1 = bk1/v1, r2 = bk2/v2. (1)
Moreover, the following equations are satisfied:
v1(v1 − 1)λ11 = bk1(k1 − 1), v2(v2 − 1)λ22 = bk2(k2 − 1), (2)
and
bk1k2 = v1v2λ12, (3)
as well as the inequality
b ≥ v1 + v2 − 1. (4)
If the design is c-partitionable then
b ≥ v1 + v2 + c− 2. (5)
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Proof The first two statements are the usual conditions for the 2-designs
on cancer types and drugs respectively, while Equation (3) equates two dif-
ferent ways of counting the number of choices of a cancer type, a drug, and
a block containing both.
For inequality (5), let N = (N>1 , N>2 , N>0 )>, where N1 and N2 are the
incidence matrices defined in Section 1.3 and N>0 is the b×c incidence matrix
of blocks in classes. Then
NN> =
 (r1 − λ11)I + λ11J λ12J (r1/c)Jλ12J (r2 − λ22)I + λ22J (r2/c)J
(r1/c)J (r2/c)J (b/c)I
 ,
where I and J are identity and all-1 matrices of the appropriate sizes.
We claim that NN> has rank v1 + v2 + c− 2, from which inequality (5)
follows. First, let w1, w2 and w3 be column vectors of lengths v1, v2, c
respectively whose entries sum to 0. Then
NN>
 w1w2
w3
 =
 (r1 − λ11)w1(r2 − λ22)w2
(b/c)w3
 . (6)
Because the blocks are incomplete, λ11 < r1 and λ22 < r2, and so the
restriction of this matrix to the space of such vectors, which has dimension
v1 + v2 + c − 3, is invertible. The orthogonal complement of this space
consists of all vectors of the form (xj>1 , yj>2 , zj>3 )>, where j1, j2 and j3 are
all-1 vectors of lengths v1, v2 and c respectively. The action of NN
> on this
space is obtained by replacing the block matrices by their row sums: using
the results in (1)–(3), this simplifies to r1k1 r1k2 r1r2k1 r2k2 r2
(b/c)k1 (b/c)k2 (b/c)
 ,
which has rank 1. So the claim (5) is proved.
The first part of the theorem shows that every 2-part 2-design is 1-
partitionable. Thus inequality (4) is a special case of inequality (5).
Remark 1 Mukerjee (1998) remarked on the integrality conditions (1)–(3)
without stating them explicitly, and proved inequality (4).
Remark 2 Inequality (4) can be regarded as a generalization of both Fisher’s
and Bose’s inequalities: see Cameron & van Lint (1991, Chapter 1) and Bai-
ley (2008, Chapter 11). For Fisher’s inequality, take the C-design to be any
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2-design with v = v1, and take a single drug which occurs in all blocks;
we have λ12 = r1 and λ22 = 0: although our conditions that λ22 > 0 and
k2 < v2 fail for the D-design, the proof still works, because the only vector
w2 in equation (6) is the zero vector: thus the proof gives b ≥ v + 1 − 1.
For Bose’s inequality, take the C-design to be any resolvable 2-design with
v = v1 and replication r = r1, and the drugs to be labelled by the resolution
classes of the design, with a drug in every block in the corresponding reso-
lution class, so that v2 = r. We have λ12 = 1 and λ22 = 0. Again part of
condition (d) fails, but the proof works, giving b ≥ v+ r− 1. Inequality (5)
seems to be the true analogue of Bose’s inequality for 2-part 2-designs.
Remark 3 Although neither triple arrays nor 2-part 2-designs are special
cases of the other, they both satisfy inequality (4). Proofs for triple arrays
are in Bagchi (1998), Bailey (2017) and McSorley et al. (2005), and the proof
that we have given here also works for triple arrays.
2 Constructions of 2-part 2-designs
In this section, we give several constructions. In order to identify when two
different constructions give designs which are essentially the same, we say
that two 2-part 2-designs are isomorphic to each other if one can be obtained
from the other by relabelling some of blocks, cancer types and drugs. Weak
isomorphism generalizes this by also allowing the roles of cancer types and
drugs to be interchanged.
Given two or more non-isomorphic designs for the same parameters,
there may be practical reasons for preferring one over the rest.
Since interchanging roles does not affect conditions (a)–(e), from now on
we usually adopt the convention that
v1 ≥ v2. (7)
Given a 2-part 2-design, the procedure of C-swap creates a new 2-part
2-design. This simply involves replacing the set of cancer treatments in each
block with the complementary set. This changes the parameters k1, λ11 and
λ12 to v1 − k1, b − 2r1 + λ11 and r2 − λ12, leaving b, v1, v2, k2 and λ22
unchanged. The new design fulfills all the conditions so long as v1− k1 ≥ 2.
The combination of a C-swap and the analogous D-swap has the effect of
replacing each block by its complement (in the zipped version).
Thus, in our search for design constructions, we may assume that
for i = 1 and i = 2, either ki ≤ vi/2 or ki = vi − 1. (8)
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Table 1: Parameter sets for the designs with the least number of blocks that
can be made by Construction 1: v1 is the number of cancer types, v2 is the
number of drugs, and b is the number of blocks, each of which has k1 cancer
types and k2 drugs
b v1 v2 k1 k2
9 3 3 2 2
12 4 3 3 2
15 5 3 4 2
16 4 4 3 3
18 4 3 2 2
18 6 3 5 2
b v1 v2 k1 k2
20 5 4 4 3
21 7 3 3 2
21 7 3 6 2
24 4 4 3 2
24 6 4 5 3
b v1 v2 k1 k2
24 8 3 7 2
25 5 5 4 4
27 9 3 8 2
28 7 4 3 3
28 7 4 6 3
b v1 v2 k1 k2
30 5 3 2 2
30 5 4 4 2
30 6 3 3 2
30 6 5 5 4
32 8 4 7 3
All of our tables are limited to parameter sets which satisfy conditions (7)
and (8).
Construction 1 (Cartesian products) One obvious method of construc-
tion is the cartesian product. This starts with two balanced incomplete-
block designs, one for v1 treatments in b1 blocks of size k1, the other for v2
treatments in b2 blocks of size k2. Form all b1b2 combinations of a block of
each sort. For each combination, form the cartesian product of their subsets
of treatments.
This will usually result in rather large values of b. For example, when
v1 = 6, k1 = 3, v2 = 5 and k2 = 2 then the smallest possible values of b1 and
b2 are both 10, so this construction gives a design with 100 blocks, unlike
the design with 10 blocks in Fig. 1.
Table 1 shows the parameters of the designs with the least number of
blocks which can be constructed by this method with v1 ≥ v2, using the
table of 2-designs in Appendix I of Hall (1986); note that design 13 in that
table should have k = 4.
Construction 2 (Subcartesian products) If k2 divides v2 then there
may exist a resolved 2-design ∆2 for v2 drugs in b2 blocks of size k2 with
r resolution classes. Suppose that ∆1 is a 2-design for v1 cancer types in
b1 blocks of size k1, where b1 is a multiple of r. Now we can achieve a
2-part 2-design without taking the full product. Partition the blocks of ∆1
into r classes of size b1/r in any way at all, and match these classes to the
resolution classes of ∆2 in any way. For each matched pair, construct the
11
Block Cancer types Drugs
1 C1, C2 D1, D3
2 C1, C2 D2, D4
3 C3, C4 D1, D3
4 C3, C4 D2, D4
5 C1, C3 D2, D3
6 C1, C3 D1, D4
7 C2, C4 D2, D3
8 C2, C4 D1, D4
9 C1, C4 D1, D2
10 C1, C4 D3, D4
11 C2, C3 D1, D2
12 C2, C3 D3, D4
Block Cancer types Drugs
1 C1, C2 D1, D3
2 C1, C2 D2, D4
3 C1, C3 D1, D3
4 C1, C3 D2, D4
5 C1, C4 D2, D3
6 C1, C4 D1, D4
7 C2, C3 D2, D3
8 C2, C3 D1, D4
9 C2, C4 D1, D2
10 C2, C4 D3, D4
11 C3, C4 D1, D2
12 C3, C4 D3, D4
(a) Constructions 2 and 3 (b) Construction 2 but not Construction 3
Figure 5: Two designs for 4 cancer types and 4 drugs, using 12 blocks; each
block has 2 cancer types and 2 drugs.
cartesian product design. Putting these products together gives a design
of the required type with b1b2/r blocks, considerably fewer than the b1b2
blocks in the entire product of ∆1 and ∆2.
More generally, if the design ∆2 is c-partitionable and c divides b1 then
replace the resolution classes in this construction by the c classes of blocks.
This gives a 2-part 2-design with b1b2/c blocks. Putting c = 1 gives Con-
struction 1 as a special case of this.
Figures 5(a) and (b) show two possibilities when v1 = v2 = 4, k1 = k2 =
2 and r = 3.
Table 2 shows some parameter sets for designs that can be made by
Construction 2, possibly after an interchange or a swap, with ki ≤ 10 for
i = 1 and i = 2.
There are two special cases. When b1 = r then we simply match the
blocks of ∆1 to the resolution classes of ∆2. When v1 = 3, k1 = 2, v2 = 4,
k2 = 2 and r = 3, this gives the design in Fig. 6. When v1 = v2 = 6,
k1 = k2 = 3 and r = 10, this gives the design in Fig. 7(a). When v1 = 7,
k1 = 3, v2 = 15, k2 = 3 and r = 7, this gives a 2-part 2-design with b = 35,
r1 = 5, r2 = 7, λ11 = 5, λ22 = 1 and λ12 = 3.
On the other hand, if ∆1 is also resolved with replication r then we
may match the resolution classes of the two designs. For example, when
12
Block Cancer types Drugs
1 C1, C2 D1, D3
2 C1, C2 D2, D4
3 C1, C3 D2, D3
4 C1, C3 D1, D4
5 C2, C3 D1, D2
6 C2, C3 D3, D4
Figure 6: Design for 3 cancer types and 4 drugs, using 6 blocks; each block
has 2 cancer types and 2 drugs.
v1 = v2 = 4 and k1 = k2 = 2 then we may take r = 3 and b1 = b2 = 6 to get
the design in Fig. 5(a). This is not even weakly isomorphic to the design in
Fig. 5(b), where the pairs of blocks from ∆1 do not form resolution classes.
When v1/k1 = v2/k2 = 2 and b1 = b2, Construction 3 also gives designs
with these parameters.
At first sight, the two general constructions given by Mukerjee (1998)
are special cases of this. His first construction needs both ∆1 and ∆2 to be
c-partitionable, and matches the classes. This includes the cartesian product
when c = 1, and when c = 3 it gives the design in Figure 5(a) but not the
one in Figure 5(b). His second construction use a c-partitionable design ∆2
only when b1 = c. However, if c divides b1 then we may replace ∆2 by b1/c
copies of it, giving a b1-partionable design whose classes can be matched to
the blocks of ∆1.
Thus Construction 2 is precisely equivalent to the combination of the
two in Mukerjee (1998).
Construction 3 (Hadamard matrices) Some 2-part 2-designs in which
v1 = v2 and k1 = k2 = v1/2 arise from Construction 2. Another way of
getting such designs is to start with a Hadamard matrix H of order 4n,
where n = k1, in which the elements in the first row are all +1. Identify
the 2n cancer types with the columns in which the second row has entry
+1, and identify the 2n drugs with the columns in which the second row
has entry −1. Each of the remaining rows gives two blocks, one containing
all the objects whose columns have entries +1, and one containing all the
objects whose columns have entries −1. Thus b = 8n − 4. Moreover, each
pair of blocks contains each cancer type and each drug just once, in the
concise representation, so the 2-part 2-design is (4n − 2)-partitionable and
the lower bound in inequality (5) is achieved.
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Block Cancer types Drugs
1 C1, C2, C3 D1, D5, D6
2 C1, C2, C3 D2, D3, D4
3 C1, C5, C6 D1, D2, D6
4 C1, C5, C6 D3, D4, D5
5 C1, C3, C4 D2, D3, D6
6 C1, C3, C4 D1, D4, D5
7 C1, C2, C6 D3, D4, D6
8 C1, C2, C6 D1, D2, D5
9 C1, C4, C5 D4, D5, D6
10 C1, C4, C5 D1, D2, D3
11 C2, C4, C5 D1, D3, D6
12 C2, C4, C5 D2, D4, D5
13 C2, C3, C5 D2, D4, D6
14 C2, C3, C5 D1, D3, D5
15 C3, C5, C6 D3, D5, D6
16 C3, C5, C6 D1, D2, D4
17 C3, C4, C6 D1, D4, D6
18 C3, C4, C6 D2, D3, D5
19 C2, C4, C6 D2, D5, D6
20 C2, C4, C6 D1, D3, D4
Block Cancer types Drugs Biomarkers
1 C1, C3, C5 D1, D4, D5 B1, B2
2 C2, C4, C6 D2, D3, D6 B1, B2
3 C1, C5, C6 D3, D5, D6 B1, B3
4 C2, C3, C4 D1, D2, D4 B1, B3
5 C1, C2, C3 D2, D3, D5 B1, B4
6 C4, C5, C6 D1, D4, D6 B1, B4
7 C1, C4, C5 D1, D2, D3 B1, B5
8 C2, C3, C6 D4, D5, D6 B1, B5
9 C1, C4, C6 D2, D4, D5 B2, B3
10 C2, C3, C5 D1, D3, D6 B2, B3
11 C1, C3, C4 D3, D4, D6 B2, B4
12 C2, C5, C6 D1, D2, D5 B2, B4
13 C1, C2, C5 D2, D4, D6 B2, B5
14 C3, C4, C6 D1, D3, D5 B2, B5
15 C1, C2, C4 D1, D5, D6 B3, B4
16 C3, C5, C6 D2, D3, D4 B3, B4
17 C1, C2, C6 D1, D3, D4 B3, B5
18 C3, C4, C5 D2, D5, D6 B3, B5
19 C1, C3, C6 D1, D2, D6 B4, B5
20 C2, C4, C5 D3, D4, D5 B4, B5
(a) Construction 2 (b) Construction 3 (ignoring the 5 biomarkers)
followed by Construction 9
Figure 7: Two designs for 6 cancer types and 6 drugs, using 20 blocks.
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For example, when n = 3 we can take
H =

+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1
+1 +1 +1 +1 +1 +1 −1 −1 −1 −1 −1 −1
+1 −1 +1 −1 +1 −1 +1 −1 −1 +1 +1 −1
+1 −1 −1 −1 +1 +1 −1 −1 +1 −1 +1 +1
+1 +1 +1 −1 −1 −1 −1 +1 +1 −1 +1 −1
+1 −1 −1 +1 +1 −1 +1 +1 +1 −1 −1 −1
+1 −1 −1 +1 −1 +1 −1 +1 −1 +1 +1 −1
+1 −1 +1 +1 −1 −1 −1 −1 +1 +1 −1 +1
+1 +1 −1 −1 +1 −1 −1 +1 −1 +1 −1 +1
+1 +1 −1 +1 −1 −1 +1 −1 −1 −1 +1 +1
+1 +1 −1 −1 −1 +1 +1 −1 +1 +1 −1 −1
+1 −1 +1 −1 −1 +1 +1 +1 −1 −1 −1 +1

.
Labelling the columns as C1, . . . , C6, D1, . . . , D6 in order, the construc-
tion gives the design in the first three columns of Fig. 7(b), ignoring the
biomarkers. It is not weakly isomorphic to the design in Fig. 7(a), because
all triples of cancer types and all triples of drugs occur.
The asterisked entries in Table 2 show the parameters of the smallest
designs that can be constructed by this method.
When n = 4 this construction gives the design in Fig. 5(a). For some
values of n, different choices of Hadamard matrix, or different designations
of which row is second, can give non-isomorphic designs. It may be that
there are some values of n for which there exists a Hadamard matrix of
order 4n but no 2-(2n, n, n− 1) design. If so, Construction 3 gives a design
for these parameters but Construction 2 does not. Such a value of n is likely
to be too large to affect designs of practical size. However, we retain this
construction, because it produces resolvable designs, which can be used as
ingredients in Construction 9 in Section 3 to give designs without too many
blocks.
Construction 4 (Symmetric 2-designs) Here is another general method
of construction. Consider a symmetric balanced incomplete-block design ∆
for v treatments in v blocks of size k. Every pair of distinct treatments
concur in λ blocks, where λ = k(k − 1)/(v − 1), and every pair of distinct
blocks have λ treatments in common. Let Γ be one block of ∆. Identify the
treatments in Γ with k drugs D1, . . . , Dk and the remaining treatments with
v − k cancer types C1, . . . , Cv−k. Now consider the design ∆′ consisting of
all blocks of ∆ except Γ. Each of these blocks contains λ drugs and k − λ
cancer types. In ∆′, each pair of drugs concur in λ − 1 blocks; each pair
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Table 2: Parameter sets for the designs with the least number of blocks
that can be made by Constructions 2 or 3 but not 1: v1 is the number
of cancer types, v2 is the number of drugs, and b is the number of blocks,
each of which has k1 cancer types and k2 drugs; r is a number used in the
construction. Asterisks denote the only parameter sets for designs achievable
by Construction 3
b v1 v2 k1 k2 r
6 4 3 2 2 3
∗ 12 4 4 2 2 3
12 9 4 3 3 4
14 8 7 4 3 7
14 8 7 4 6 7
15 6 5 2 4 5
18 9 4 8 2 3
20 6 5 3 2 10
∗ 20 6 6 3 3 5
20 16 5 4 4 5
22 12 11 6 5 11
22 12 11 6 10 11
24 9 4 3 2 3
24 9 8 3 7 4
b v1 v2 k1 k2 r
28 8 7 2 3 7
28 8 7 2 6 7
∗ 28 8 8 4 4 7
30 6 4 2 2 3
30 6 5 2 2 5
30 6 6 3 2 5
30 10 4 4 2 3
30 15 4 7 2 3
35 15 7 3 3 7
35 15 7 3 6 7
36 9 4 4 2 3
36 9 9 3 3 4
36 10 4 9 2 3
∗ 36 10 10 5 5 9
b v1 v2 k1 k2 r
40 16 5 4 2 5
40 16 6 4 3 5
42 7 4 2 2 3
42 8 7 4 2 7
42 21 4 5 2 3
42 21 8 5 4 7
∗ 44 12 12 6 6 11
45 6 6 2 2 5
45 10 6 4 2 5
45 15 6 7 2 5
48 16 4 6 2 3
48 16 9 6 3 4
∗ 52 14 14 7 7 13
54 27 4 13 2 3
b v1 v2 k1 k2 r
56 8 8 4 2 7
60 10 4 3 2 3
60 10 6 3 3 10
60 16 4 8 2 3
60 16 6 4 2 5
60 16 6 8 3 10
60 16 9 4 3 4
60 16 10 4 4 5
60 16 15 4 7 5
∗ 60 16 16 8 8 15
60 21 4 7 2 3
60 21 6 7 3 10
60 25 4 5 2 3
60 25 6 5 3 10
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Table 3: Parameter sets for which small designs can be made by Construc-
tion 4: v1 is the number of cancer types, v2 is the number of drugs, and b is
the number of blocks, each of which has k1 cancer types and k2 drugs; v, k
and λ are parameters of the symmetric 2-design used in the construction
b v1 v2 k1 k2 v k λ
6 4 3 2 2 7 4 2
10 6 5 3 2 11 5 2
12 9 4 6 3 13 9 6
b v1 v2 k1 k2 v k λ
14 8 7 4 3 15 7 3
15 10 6 4 2 16 6 2
18 10 9 5 4 19 9 4
b v1 v2 k1 k2 v k λ
22 12 11 6 5 23 11 5
24 16 9 6 3 25 9 3
of cancer types concur in λ blocks; and each drug occurs with each cancer
type in λ blocks. Thus b = v − 1, v1 = v − k, v2 = k, k1 = k − λ, k2 = λ,
λ11 = λ12 = λ and λ22 = λ− 1.
We can use Construction 4 whenever there exists a symmetric 2-(v, k, λ)
design with v = v1 + v2, k = v2 and λ = k2, provided that k1 + k2 = v2. In
order to satisfy condition (d), λ must be bigger than one. The lower bound
in inequality (4) is always met.
The properties of symmetric 2-designs guarantee that conditions (c) and
(d) hold, but they also match up the blocks of the C-design and the D-design,
which typically produces fewer blocks than previous construction methods.
The design in Fig. 1 can be obtained by this construction with v = 11,
k = 5 and λ = 2. Figure 6 gives the design with v = 7, k = 4 and λ = 2.
Table 3 lists parameter sets for small designs that can be constructed by
this method, with an interchange and swaps where necessary: again using
Table I.1 in Hall (1986). After allowing for possible interchanges and swaps,
this table represents 34 designs.
Construction 5 (Augmentation) Given a 2-part 2-design ∆ in which
v2 = 2k2 + 1, we may augment it to one for one more drug by increasing
v2 to v2 + 1 and k2 to k2 + 1 while merely doubling the number of blocks.
Replace each block of ∆ by two blocks, both with the same set of cancer
types as before. One of these blocks has the previous set of drugs and the
extra drug, while the other has all the remaining drugs.
For example, augmenting the design in Fig. 1 gives the design in Fig. 7(a).
Applying the augmentation just to the D-design gives a resolvable 3-
design, as shown in the Extension Theorem of Alltop (1972). This can be
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used directly in Construction 2. However, augmentation is such a straight-
forward way of obtaining one 2-part 2-design from another that we think it
is worth identifying.
Construction 6 (Group-divisible designs) If v1 = v2 = v and k1 =
k2 = k then the zipped form of a 2-part 2-design is a semi-regular group-
divisible incomplete-block design for two so-called groups of v treatments in
blocks of size 2k with k > 1: see Bose & Connor (1952). Unzipping any one
of these gives a 2-part 2-design.
Table VII of Clatworthy (1973) gives three such designs. Unzipping them
gives the product design for the first parameter set in Table 1, the design in
Fig. 5(a) and the design in the first three columns of Fig. 7(b).
Construction 7 (Group actions) Here is a construction based on group
actions. Suppose that the group G acts 2-transitively on two sets C and D
of sizes v1 and v2 respectively, and that G is also transitive in the induced
action on C×D. Choose a subset of C and a subset of D, each containing at
least two points; their union is a block, and the images of this block under G
give the remaining blocks. The blocks have to be unzipped to give a 2-part
2-design. This does not give much control over b, except that we know it
is a divisor of the order of G. A strategy for finding good designs by this
method is to choose a subgroup H of G which acts intransitively on each of
C and D, and to use fixed sets of H on C and D in the construction.
The three examples below arise from this construction, but can be more
easily be derived from the 3-(22, 6, 1) design Ξ whose automorphism group
is the Mathieu group M22. It has 22 points and 77 blocks of size 6, any
two blocks meeting in zero or two points; see Cameron & van Lint (1991,
Chapters 1 and 9). For simplicity, we describe the cancer types as red points
and the drugs as green points.
Take a block B0 of the design Ξ; its points are red, and the remaining
16 points are green. For each of the 60 blocks meeting B0 in two points, we
define a block of our new design containing two red and four green points.
Now two red points lie in five blocks, one of which is B0; so they lie in four
more blocks. A red and green point lie in five blocks, each containing two
red points. Two green points lie in three blocks meeting B0. For each point
of B0 lies in a unique such block, and each block contains two points of B0.
So we have an example with v1 = 6, v2 = 16, b = 60, k1 = 2, k2 = 4, and
(λ11, λ12, λ22) = (4, 5, 3).
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Table 2 shows these parameters for a design made by Construction 2 and
an interchange.
The other two examples use the 4-(23, 7, 1) design Θ in which the blocks
through the extra point are formed by adjoining that point to the blocks
of Ξ: see Cameron & van Lint (1991). The counting arguments that verify
their properties are similar to what we have just seen.
For the second design, we take a set A of seven points which form a block
of Θ not containing the extra point. These will be red, and the remaining
15 points of Ξ green. Any block of Ξ meets A in one or three points; we
take the blocks meeting A in three points to be the blocks of the required
design. We obtain an example with v1 = 7, v2 = 15, b = 35, k1 = k2 = 3,
and (λ11, λ12, λ22) = (5, 3, 1).
This has the same parameters as the fifth design made using Construc-
tion 2.
Finally, using the 23-point design Θ but not throwing away the ex-
tra point we obtain a design with v1 = 7, v2 = 16, k1 = 3, k2 = 4,
(λ11, λ12, λ22) = (20, 15, 7), b = 140. Another design with these parame-
ters is the cartesian product of the projective plane of order 2 and the affine
plane of order 4; these designs are not isomorphic.
To build these from the group action construction, the relevant groups
are the stabilizers of the sets of six or seven red points in the appropriate
Mathieu groups; these are the groups 24:S6, A7, and 2
4:A7 respectively.
3 Generalizing the design problem
3.1 The extended problem
In March 2016 Valerii Fedorov extended the problem as follows. Can we
add a third factor, whose levels are biomarkers in this case, subject to the
obvious extra conditions? Here we generalize this to an arbitrary number
m of factors.
The conditions for an m-part 2-design are as follows. The analogue
of conditions (a)–(b) is that, for 1 ≤ i ≤ m, factor i has vi levels and each
medical centre involves ki of them, where ki < vi; the analogue of conditions
(c)–(d) is that, for 1 ≤ i ≤ m, each pair of levels of factor i are used together
at the same non-zero number λii of medical centres.
The generalization of condition (e) is less clear. When i = 3, a weak
generalization is that each biomarker is used on each cancer type at the
same number λ13 of medical centres and that each biomarker is used with
each drug at the same number λ23 of medical centres. For now, we use
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this weak version. Note, however, that this gets us into the territory of
factorial design, so we might be confounding all or part of a two-factor
interaction with all or part of a main effect. By analogy with orthogonal
arrays (Hedayat et al., 1999), we call this weak generalization a 3-part 2-
design with strength 2, whereas a 3-part 2-design with strength 3 would have
every triple of (cancer type, drug, biomarker) at the same number λ123 of
medical centres.
Thus the strength-2 generalization of condition (e) is that, for 1 ≤ i <
j ≤ m, each level of factor i occurs with each level of factor j at the same
number λij of medical centres.
3.2 Conditions on parameters in the extended problem
Theorem 2 In an m-part 2-design of strength 2, all of the following are
satisfied.
(i) The analogues of equations (1) and (2) hold for each factor.
(ii) Equation (3) generalizes to bkikj = vivjλij for 1 ≤ i < j ≤ m.
(iii) If the design is c-partitionable then b ≥ v1 + · · ·+ vm + c−m.
(iv) In particular, b ≥ v1 + · · ·+ vm −m+ 1.
Proofs are similar to those in Section 1.5. Part (iv) is precisely Theorem 1
of Mukerjee (1998).
4 Constructions of m-part 2-designs of strength at
least 2
4.1 Two main constructions
Here we give the main construction of Mukerjee (1998) in the language of
this paper.
Construction 8 (Orthogonal arrays) Suppose that there is a positive
integer c such that, for i = 1, . . . , m, ∆i is a c-partitionable 2-design for vi
treatments in bi blocks of size ki. Moreover, there is an orthogonal array Γ
with m columns, where column i contains bi/c symbols for 1 ≤ i ≤ m.
Match the c classes of blocks of ∆1, . . . , ∆m. For j = 1, . . . , c separately,
each row ρ of Γ gives a block of the new design, as follows. For i = 1, . . . ,
m, identify the block in class j of ∆i labelled by the symbol in row ρ and
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Cancer Bio-
Block types Drugs markers
1 C1, C2 D1, D2 B1, B2
2 C1, C3 D1, D3 B1, B3
3 C2, C3 D2, D3 B2, B3
4 C1, C2 D2, D3 B1, B3
5 C1, C3 D1, D2 B2, B3
6 C2, C3 D1, D3 B1, B2
7 C1, C2 D1, D3 B2, B3
8 C1, C3 D2, D3 B1, B2
9 C2, C3 D1, D2 B1, B3
Cancer Bio-
Block types Drugs markers
1 C1, C2 D1, D2 B1, B2
2 C1, C2 D3, D4 B3, B4
3 C3, C4 D1, D2 B3, B4
4 C3, C4 D3, D4 B1, B2
5 C1, C3 D1, D3 B1, B3
6 C1, C3 D2, D4 B2, B4
7 C2, C4 D1, D3 B2, B4
8 C2, C4 D2, D4 B1, B3
9 C1, C4 D1, D4 B1, B4
10 C1, C4 D2, D3 B2, B3
11 C2, C3 D1, D4 B2, B3
12 C2, C3 D2, D3 B1, B4
(a) 3 cancer types, 3 drugs, 3 biomarkers (b) 4 cancer types, 4 drugs, 4 biomarkers
Figure 8: Two 3-part 2-designs, both made from Construction 8
column i of Γ: then form the cartesian product of these m blocks. This
gives a c-partitionable m-part 2-design in sc blocks, where s is the number
of rows of Γ. The strength of this new design is equal to the strength of the
orthogonal array Γ.
In one extreme case, Γ has all possible different rows, so that s =∏m
i=1 bi/c
m. If, in addition, c = 1, then s =
∏m
i=1 bi and we obtain the
full cartesian product.
The design in Fig. 8(a) can be made in this way with c = 1, using an
orthogonal array with three columns, each with three symbols.
An example with m = 3 and c = 2 is shown in Fig. 8(b), which is
contained in Table 1 of Mukerjee (1998). Here, vi = 4, ki = 2 and bi = 6 for
i = 1, 2, 3, and each of ∆1, ∆2 and ∆3 can be resolved into pairs of blocks.
For each design, label the replicates 1, 2, 3 in any order. For j = 1, 2, 3,
combine the j-th replicates from the three designs, not by the full cartesian
product, which would give eight blocks, but by using an orthogonal array of
strength 2 with four rows and three columns, each with two symbols. This
3-part 2-design has strength 2 but not strength 3.
Table 1 of Sitter (1993) gives a 7-part 2-design made in this way with
b = 24 and vi = 2ki = 4 for i = 1, . . . , 7.
Construction 9 (Products of multi-part designs) The ingredients of
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the previous construction are m individual 2-designs and an orthogonal ar-
ray, which may be trivial. Instead, we may start with multi-part 2-designs,
or an assortment of 2-designs and multi-part 2-designs. The use of orthog-
onal arrays and/or c-partitioning can be extended to this method too. As
in Construction 2, we can allow one of the constituent designs to be not
c-partitionable, as long as its number b of blocks is divisible by c.
The full product of an m1-part 2-design Θ1 with b1 blocks and an m2-
part 2-design Θ2 with b2 blocks is an (m1 + m2)-part 2-design with b1b2
blocks and strength 2. If Θ1 has strength m1 and m2 = 1 then the full
product has strength m1 + 1. For example, if m = 3, v3 = 3 and k3 = 2
then the product of the design in Fig. 1 and a 2-design with three blocks of
size 2 gives a 3-part 2-design with 30 blocks and strength 3.
As an example of the relaxation of the c-partitionable condition, suppose
that Θ is a c-partitionable m1-part 2-design for drugs and cancer types and
∆ is a 2-design for v3 biomarkers in c blocks of size k3. We can simply
match the blocks of ∆ to the classes of Θ in any way. The 3-part 2-design
in Fig. 7(b) was made like this by starting with a 2-part 2-design made by
Construction 3, grouping blocks into ten classes of the form {2i−1, 2i}, and
matching these classes to the ten blocks of a 2-design ∆ for five biomarkers.
The special case of this with b = c is the second general construction
given by Mukerjee (1998). As noted in Section 2, this specialization does not
restrict his designs. However, because we have now given more constructions
for the case that m = 2, applying the various product constructions to them
produces new designs for higher values of m also.
4.2 Other constructions
The augmentation method in Construction 5 easily generalizes to three or
more factors. If vi = 2ki + 1 then vi and ki can be increased by one while
the number of blocks is merely doubled.
If v1 = · · · = vm = v and k1 = · · · = km = k then the zipped form of an
m-part 2-design is a semi-regular group-divisible design for mv treatments
in blocks of size mk with k > 1. Just as in Construction 6, any such design
can be unzipped to give a m-part 2 design. There are two such designs with
m = 3 in Table VII of Clatworthy (1973). Their unzipped forms are the
designs in Fig. 8. The one with m = 4 gives the design in Figure 9, which
can also be obtained from a 9 × 4 orthogonal array with three symbols in
each column.
The group method in Construction 7 also easily extends to three or more
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Cancer Bio-
Block types Drugs markers Activity
1 C1, C2 D1, D2 B1, B2 A1, A2
2 C1, C2 D2, D3 B2, B3 A1, A3
3 C1, C2 D1, D3 B1, B3 A2, A3
4 C1, C3 D1, D2 B2, B3 A2, A3
5 C1, C3 D2, D3 B1, B3 A1, A2
6 C1, C3 D1, D3 B1, B2 A1, A3
7 C2, C3 D1, D2 B1, B3 A1, A3
8 C2, C3 D2, D3 B1, B2 A2, A3
9 C2, C3 D1, D3 B2, B3 A1, A2
Figure 9: A 4-part 2-design
factors: simply take a permutation group with more than two 2-transitive
actions.
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